Search

Your search keyword '"OVERALL survival"' showing total 2 results
2 results on '"OVERALL survival"'

Search Results

1. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.

2. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.

Catalog

Books, media, physical & digital resources